Bladder cancer, version 5.2017: Clinical practice guidelines in oncology

摘要: This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy muscle-invasive urothelial bladder cancer, as substantial revisions were made 2017 updates, such new recommendations nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of addresses additional aspects management including non-muscle-invasive cancer nonurothelial histologies, well staging, evaluation, follow-up.